CL2022000522A1 - Lurbinectedina en el tratamiento del mesotelioma maligno. - Google Patents

Lurbinectedina en el tratamiento del mesotelioma maligno.

Info

Publication number
CL2022000522A1
CL2022000522A1 CL2022000522A CL2022000522A CL2022000522A1 CL 2022000522 A1 CL2022000522 A1 CL 2022000522A1 CL 2022000522 A CL2022000522 A CL 2022000522A CL 2022000522 A CL2022000522 A CL 2022000522A CL 2022000522 A1 CL2022000522 A1 CL 2022000522A1
Authority
CL
Chile
Prior art keywords
lurbinectedin
treatment
malignant mesothelioma
mesothelioma
malignant
Prior art date
Application number
CL2022000522A
Other languages
English (en)
Inventor
Ioannis Metaxas
Moos Roger Von
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of CL2022000522A1 publication Critical patent/CL2022000522A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se proporciona el uso de Lurbinectedina en el tratamiento del mesotelioma maligno.
CL2022000522A 2019-09-03 2022-03-02 Lurbinectedina en el tratamiento del mesotelioma maligno. CL2022000522A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19382749 2019-09-03

Publications (1)

Publication Number Publication Date
CL2022000522A1 true CL2022000522A1 (es) 2022-10-21

Family

ID=67902455

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022000522A CL2022000522A1 (es) 2019-09-03 2022-03-02 Lurbinectedina en el tratamiento del mesotelioma maligno.

Country Status (13)

Country Link
US (1) US20230241041A1 (es)
EP (1) EP4025217A1 (es)
JP (1) JP2022547049A (es)
KR (1) KR20220054872A (es)
CN (1) CN114423429A (es)
AU (1) AU2020342483A1 (es)
BR (1) BR112022003149A2 (es)
CA (1) CA3148690A1 (es)
CL (1) CL2022000522A1 (es)
IL (1) IL290656A (es)
MX (1) MX2022002699A (es)
TW (1) TW202116783A (es)
WO (1) WO2021043949A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230061434A (ko) * 2020-09-04 2023-05-08 파르마 마르, 에스.에이. 루비넥테딘 및 면역 체크포인트 억제제의 조합

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0119243D0 (en) 2001-08-07 2001-10-03 Pharma Mar Sa Antitumoral analogs of ET-743
CN106974902A (zh) * 2016-01-18 2017-07-25 贵州益佰制药股份有限公司 洛铂在制备治疗恶性胸膜间皮瘤药物中的应用

Also Published As

Publication number Publication date
US20230241041A1 (en) 2023-08-03
MX2022002699A (es) 2022-04-11
IL290656A (en) 2022-04-01
CN114423429A (zh) 2022-04-29
CA3148690A1 (en) 2021-03-11
EP4025217A1 (en) 2022-07-13
JP2022547049A (ja) 2022-11-10
WO2021043949A1 (en) 2021-03-11
TW202116783A (zh) 2021-05-01
KR20220054872A (ko) 2022-05-03
BR112022003149A2 (pt) 2022-05-17
AU2020342483A1 (en) 2022-04-14

Similar Documents

Publication Publication Date Title
CL2019001874A1 (es) Inhibidores de tgfß1 isoforma-específicos contexto-permisivos y uso de los mismos.
CO2021001912A2 (es) Composiciones anti-cd112r y métodos
CO2020016619A2 (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
CL2016002516A1 (es) “compuestos derivados de espirociclo sustituidos, inhibidores atx; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer, inflamaciones, dolor neuropático, enfermedades fibróticas, trombosis, entre otros”. pct
BR112019005908A2 (pt) uso de combinação de anticorpo anti-pd-1 e inibidor de vegfr na preparação de fármaco para tratamento de cânceres
CL2016003422A1 (es) Inhibidores de demetilasa-1 específico de lisina
CO2020015923A2 (es) Antagonista de gremlin-1 para la prevención y tratamiento del cáncer
CL2016001840A1 (es) Compuestos derivados de pirimidinas fusionadas como inhibidores del complejo p97; composicion farmaceutica y uso en el tratamiento del cancer.
CL2016003423A1 (es) Inhibidores de demetilasa-1 específico de lisina
CL2016001609A1 (es) Composiciones farmacéuticas que comprenden azd9291.
CL2016002835A1 (es) “compuestos derivados de pladienolida con un resto piridinico; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct
AR112102A1 (es) Tinostamustina para utilizar en el tratamiento de cáncer de ovario
CL2015002897A1 (es) Inhibidores de bace1
CL2016002223A1 (es) Microorganismo recombinante que expresa análogos de avermectina y uso de los mismos.
BR112017004444A2 (pt) novos anticorpos anti-mfi2 e métodos de uso
CL2016001937A1 (es) Compuestos de benzopirano funcionalizados y uso de los mismos
TWD190550S (zh) 麥克風之部分
CO2018008449A2 (es) Derivados de 3-(carboximetil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
CL2018001913A1 (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
PH12021550122A1 (en) Solubilized apyrases, methods and use
CL2022000522A1 (es) Lurbinectedina en el tratamiento del mesotelioma maligno.
CL2018000941A1 (es) Regulación del uso de nitrógeno
CO2022000214A2 (es) Composiciones para el tratamiento de la pérdida del cabello
CO2021014351A2 (es) Derivados de quinolina y su uso para el tratamiento del cáncer